Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.
Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.
Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.
Glucotrack, Inc. (Nasdaq: GCTK) announced that two abstracts have been accepted for poster presentation at the American Diabetes Association 84th Scientific Sessions. The abstracts will cover preclinical data and sensor longevity modeling of the Continuous Blood Glucose Monitor (CBGM). The presentation will take place on June 22, 2024, in Orlando, FL. This conference is a prestigious platform for diabetes research and care innovations. Glucotrack aims to revolutionize continuous glucose monitoring with less intrusion into daily life. The company's CEO, Paul V. Goode, Ph.D., is eager to share the groundbreaking data with the diabetes community.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
